| Detected | Trial | Change |
|---|---|---|
| 2026-06-11 | NCT07413939 RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People… |
Trial sites expanded: 4 -> 55 locations |
| 2026-06-05 | NCT05253651 A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in… |
date change Primary completion pushed: 2026-04-03 -> 2027-12-31 |
| 2026-06-05 | NCT05253651 A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in… |
date change Completion pushed: 2029-07-27 -> 2030-07-03 |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT05253651 | A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in… | Colorectal Neoplasms | Recruiting |
| NCT03975647 | A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1)… | HER2-positive Breast Cancer | Active, Not Recruiting |
| NCT05132582 | A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+… | HER2 Positive Breast Cancer | Active, Not Recruiting |
| Phase 2/3 | |||
| NCT07413939 | RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People… | HER2-positive Breast Cancer | Recruiting |
| Phase 2 | |||
| NCT05673928 | A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With… | Metastatic Solid Tumor | Recruiting |
| NCT06016387 | Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in… | HER2-positive Breast Cancer | Recruiting |
| NCT07193394 | Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer | Metastatic Breast Cancer ( HER2 Negative) | Recruiting |
| NCT05748834 | Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor… | Breast Cancer | Recruiting |
| NCT03297606 | Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) | Lymphoma, Non-Hodgkin | Recruiting |
| NCT05458674 | Tucatinib+Trastuzumab+Eribulin in HER2+ MBC | Breast Cancer | Recruiting |
| NCT06157892 | A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors | Breast Neoplasms | Recruiting |
| NCT05672524 | A Study of Tucatinib and Trastuzumab in People With Rectal Cancer | Adenocarcinoma of the Rectum | Recruiting |
| NCT04721977 | A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in… | Breast Cancer | Active, Not Recruiting |
| NCT05892068 | A Study of Tucatinib Given Before Surgery to People With HER2+ Cancers That Have Spread… | Metastatic Breast Cancer | Active, Not Recruiting |
| NCT04430738 | Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing… | Colorectal Carcinoma | Active, Not Recruiting |
| NCT05323955 | Secondary BRain Metastases Prevention After Isolated Intracranial Progression on… | Brain Metastases | Active, Not Recruiting |
| Phase 1/2 | |||
| NCT06686394 | Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2… | Breast Neoplasms | Recruiting |
| NCT05230810 | Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic… | HER2-positive Metastatic Breast Cancer | Active, Not Recruiting |
| NCT07494448 | Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive… | HER 2 Positive Advanced Breast Cancer | Not Yet Recruiting |
| NCT05319873 | Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer | Anatomic Stage II Breast Cancer AJCC v8 | Active, Not Recruiting |
| Phase 1 | |||
| NCT05382364 | Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer… | Metastatic HER2+ Advanced Breast Cancer | Active, Not Recruiting |
| Early Phase 1 | |||
| NCT07318389 | ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic… | Dynamic Tumor Resistance | Not Yet Recruiting |